Surefire Infusion System Used In Potential New Hunger-Reducing Obesity Treatment — NIH Funds Johns Hopkins Study
Minimally invasive treatment as an alternative to bariatric surgery on the horizon
The Bariatric Arterial Embolization research at Johns Hopkins Medicine, led by principal investigators,
The procedure precisely targets the fundus, the area of the stomach that produces ghrelin or the ‘hunger hormone.’ Multiple pharmacological attempts to curb ghrelin, a gastric hormone that stimulates hunger, have been largely unsuccessful.
The novel Surefire Infusion technology, with its unique expandable antireflux tip, was chosen for its ability to:
- Improve targeting
- Prevent reflux into healthy, non-target tissue
- Achieve deeper penetration of the X-Ray visible embolic beads (XEBs) developed for this study
“Bariatric Embolization will be the world’s first image-guided, minimally invasive procedure targeting obesity that could be a viable alternative to bariatric surgery,” said
About Surefire Medical
Surefire Medical, Inc., based in
SOURCE Surefire Medical, Inc.